Abstract
As patients with metastatic bone disease typically receive long-term treatment with bisphosphonates, and often antineoplastic compounds, drug-related safety is of considerable importance. Clinical trial data for intravenous (i.v.) ibandronate suggest that its nephrotoxic potential is comparable with placebo. We conducted a post hoc Kaplan-Meier analysis of time to serum creatinine increase with i.v. ibandronate throughout 2 years of treatment. After 96 weeks, 12% of patients in the placebo group and 6% in the ibandronate 6 mg group (ns, P = 0.22) had defined serum creatinine increases. After 12 treatment months (48 weeks), 4% of patients receiving placebo and 2% of patients receiving ibandronate 6 mg showed increased serum creatinine. These results suggest that there is no clinically relevant change in serum creatinine levels with i.v. ibandronate 6 mg infused every 3-4 weeks for 2 years. Comparative trials to examine the renal safety of ibandronate and other i.v. bisphosphonates are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 299-302 |
Number of pages | 4 |
Journal | European journal of cancer care |
Volume | 15 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2006 |
Externally published | Yes |
Keywords
- Breast cancer
- Ibandronate
- Intravenous bisphosphonates
- Metastatic bone disease
- Renal impairment
ASJC Scopus subject areas
- Oncology